cis-Cyclobutan-1,2-dicarbonsaeure-diethylester | 10268-82-3

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: cis-Cyclobutan-1,2-dicarbonsaeure-diethylester
• 英文别名: diethyl (1R,2S)-cyclobutane-1,2-dicarboxylate；diethyl (1S,2R)-cyclobutane-1,2-dicarboxylate
• CAS: 10268-82-3
• 化学式: C₁₀H₁₆O₄
• 分子量: 200.235
• InChiKey: QAGGDTTXACRADK-OCAPTIKFSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.2
• 重原子数：
  14
• 可旋转键数：
  6
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.8
• 拓扑面积：
  52.6
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  cis-Cyclobutan-1,2-dicarbonsaeure-diethylester 在 lithium aluminium tetrahydride 、 乙醚 、 sodium ethanolate 作用下， 生成 trans-(cyclobutane-1,2-diyl)dimethanol
  参考文献：
  名称：

  The Relative Stabilities of cis and trans Isomers. V. The Bicyclo[5.2.0]nonanes. An Extension of the Conformational Rule^1,2

  摘要：

  DOI：

  10.1021/ja01524a064
• 作为产物：
  描述：

  顺式-环丁烷-1,2-二羧酸 在 乙醇 作用下， 生成 cis-Cyclobutan-1,2-dicarbonsaeure-diethylester
  参考文献：
  名称：

  Cyclobutane Derivatives. I.¹ The Degradation of cis- and trans-1,2-Cyclobutane-dicarboxylic Acids to the Corresponding Diamines

  摘要：

  DOI：

  10.1021/ja01263a048

文献信息

• [EN] 6-CYCLOALKYL-1, 5-DIHYDRO-PYRAZOLO [3, 4-D] PYRIMIDIN-4-ONE DERIVATIVES AND THEIR USE AS PDE9A INHIBITORS<br/>[FR] DÉRIVÉS DE 6-CYCLOALKYL-1,5-DIHYDRO-PYRAZOLO[3,4-D]PYRIMIDIN-4-ONE ET LEURS UTILISATIONS EN TANT QU'INHIBITEURS DE PDE9A
  申请人：BOEHRINGER INGELHEIM INT

  公开号：WO2012020022A1

  公开（公告）日：2012-02-16

  The invention relates to novel 6-Cycloalkyl-pyrazolopyrimidinones according to formula (I) wherein R1 is a 5 or 6 membered aromatic heteroaryl-group, R2 is an optional substituent, D is optionally substituted cyclopentyl, cyclohexyl, tetrahydrofuranyl, tetrahydropyranyl or 2-, 3- or 4-pyridyl, m= 1 or 2 and n is 0, 1 or 2. The new compounds are for use as the active entity of medicaments or for the manufacture of medicaments respectively, in particular medicaments for the treatment of conditions concerning deficits in perception, concentration, learning or memory. Such conditions may for example be associated with Alzheimers disease, schizophrenia and other diseases. The new compounds are also for example for the manufacture of medicaments and/or for use in the treatment of these diseases, in particular for cognitive impairment associated with such disease. The compounds of the invention show PDE9 inhibiting properties.

  该发明涉及根据式(I)的新型6-环烷基吡唑吡嘧啶酮，其中R1是5或6成员芳香杂环基团，R2是可选取代基，D是可选取代的环戊基、环己基、四氢呋喃基、四氢吡喃基或2-、3-或4-吡啶基，m=1或2，n为0、1或2。这些新化合物可用作药物的活性成分或用于制造药物，特别是用于治疗涉及感知、注意力、学习或记忆缺陷的疾病的药物。这些疾病可能与阿尔茨海默病、精神分裂症和其他疾病有关。这些新化合物还可用于制造药物和/或用于治疗这些疾病，特别是与此类疾病相关的认知障碍。该发明的化合物显示PDE9抑制特性。
• 6-Cycloalkyl-pyrazolopyrimidinones for the Treatment of CNS Disorders
  申请人：Heine Niklas

  公开号：US20120202829A1

  公开（公告）日：2012-08-09

  The invention relates to novel 6-Cycloalkyl-pyrazolopyrimidinones according to formula (I). wherein R 1 is a 5 or 6 membered aromatic heteroaryl-group, R 2 is an optional substituent, D is optionally substituted cyclopentyl, cyclohexyl, tetrahydrofuranyl, tetrahydropyranyl or 2-, 3- or 4-pyridyl, m=1 or 2 and n is 0, 1 or 2. The new compounds are for use as the active entity of medicaments or for the manufacture of medicaments respectively, in particular medicaments for the treatment of conditions concerning deficits in perception, concentration, learning or memory. Such conditions may for example be associated with Alzheimer's disease, schizophrenia and other diseases. The new compounds are also for example for the manufacture of medicaments and/or for use in the treatment of these diseases, in particular for cognitive impairment associated with such disease. The compounds of the invention show PDE9 inhibiting properties.

  该发明涉及根据式(I)的新型6-环烷基吡唑吡嘧啶酮。 其中R1是5或6成员芳香杂环基团，R2是可选取代基，D是可选取代的环戊基、环己基、四氢呋喃基、四氢吡喃基或2-、3-或4-吡啶基，m=1或2，n为0、1或2。 这些新化合物可用作药物的活性成分或用于制造药物，特别是用于治疗涉及感知、注意力、学习或记忆缺陷的疾病的药物。这些疾病可能与阿尔茨海默病、精神分裂症和其他疾病有关。这些新化合物还可用于制造药物和/或用于治疗这些疾病，特别是与这些疾病相关的认知障碍。该发明的化合物显示PDE9抑制特性。
• [EN] 6-CYCLOALKYL-PYRAZOLOPYRIMIDINONES FOR THE TREATMENT OF CNS DISORDERS<br/>[FR] 6-CYCLOALKYL-PYRAZOLOPYRIMIDINONES POUR LE TRAITEMENT DE TROUBLES DU SYSTÈME NERVEUX CENTRAL
  申请人：BOEHRINGER INGELHEIM INT

  公开号：WO2012110441A1

  公开（公告）日：2012-08-23

  The invention relates to novel pyrazolopyrimidinones according to formula (I), wherein X is CRe or unsubstituted N, D is optionally substituted cyclopentyl, cyclohexyl, tetrahydrofuranyl, tetrahydropyranyl or 2-, 3- or 4-pyridyl, Ra, Rb, Rc, Rd, Re are either H or optional substituents, m= 1 or 2 and n is 0, 1 or 2. The new compounds are for use as the active entity of medicaments or for the manufacture of medicaments respectively, in particular medicaments for the treatment of conditions concerning deficits in perception, concentration, learning or memory. Such conditions may for example be associated with Alzheimer's disease, schizophrenia and other diseases. The new compounds are also for example for the manufacture of medicaments and/or for use in the treatment of these diseases, in particular for cognitive impairment associated with such disease. The compounds of the invention show PDE9 inhibiting properties.

  该发明涉及新型吡唑吡咯嘧啶酮化合物，其化学式为(I)，其中X是CRe或未取代的N，D是可选择取代的环戊基、环己基、四氢呋喃基、四氢吡喃基或2-、3-或4-吡啶基，Ra、Rb、Rc、Rd、Re为H或可选择的取代基，m=1或2，n为0、1或2。这些新化合物可用作药物的活性成分或用于制造药物，特别用于治疗涉及感知、注意力、学习或记忆缺陷的疾病。这些疾病可能与阿尔茨海默病、精神分裂症和其他疾病有关。这些新化合物还可用于制造药物和/或用于治疗这些疾病，特别是与这些疾病相关的认知障碍。该发明的化合物具有PDE9抑制特性。
• Stereoselective Synthesis of Cyclobutanes by Contraction of Pyrrolidines
  作者：Chunngai Hui、Lukas Brieger、Carsten Strohmann、Andrey P. Antonchick

  DOI：10.1021/jacs.1c10175

  日期：2021.11.17

  contractive synthesis of multisubstituted cyclobutanes containing multiple stereocenters from readily accessible pyrrolidines using iodonitrene chemistry. Mediated by a nitrogen extrusion process, the stereospecific synthesis of cyclobutanes involves a radical pathway. Unprecedented unsymmetrical spirocyclobutanes were prepared successfully, and a concise, formal synthesis of the cytotoxic natural product

  在这里，我们报告了使用碘氮烯化学从容易获得的吡咯烷中收缩合成含有多个立体中心的多取代环丁烷。在氮挤压过程的介导下，环丁烷的立体定向合成涉及自由基途径。成功制备了史无前例的不对称螺环丁烷，并报道了细胞毒性天然产物哌拉硼烯 B 的简明、正式合成。
• 6-CYCLOALKYL-PYRAZOLOPYRIMIDINONES FOR THE TREATMENT OF CNS DISORDERS
  申请人：HEINE Niklas

  公开号：US20130040955A1

  公开（公告）日：2013-02-14

  The invention relates to novel pyrazolopyrimidinones according to formula (I). wherein X is CR e or unsubstituted N, D is optionally substituted cyclopentyl, cyclohexyl, tetrahydrofuranyl, tetrahydropyranyl or 2-, 3- or 4-pyridyl, R a , R b , R c , R d , R e are either H or optional substituents, m=1 or 2 and n is 0, 1 or 2. The new compounds are for use as the active entity of medicaments or for the manufacture of medicaments respectively, in particular medicaments for the treatment of conditions concerning deficits in perception, concentration, learning or memory. Such conditions may for example be associated with Alzheimer's disease, schizophrenia and other diseases. The new compounds are also for example for the manufacture of medicaments and/or for use in the treatment of these diseases, in particular for cognitive impairment associated with such disease. The compounds of the invention show PDE9 inhibiting properties.

  该发明涉及根据式(I)的新型吡唑吡咯嘧啶酮，其中X是CRe或未取代的N，D是可选择取代的环戊基、环己基、四氢呋喃基、四氢吡喃基或2-、3-或4-吡啶基，Ra、Rb、Rc、Rd、Re分别为H或可选择的取代基，m=1或2，n为0、1或2。新化合物可用作药物的活性成分或用于制造药物，特别是用于治疗涉及感知、注意力、学习或记忆缺陷的病症的药物。这些病症可能与阿尔茨海默病、精神分裂症和其他疾病有关。这些新化合物也可用于制造药物和/或用于治疗这些疾病，特别是与此类疾病相关的认知障碍。该发明的化合物显示PDE9抑制性能。

表征谱图